fludarabine has been researched along with Peripheral Nerve Diseases in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chaudhry, HM; Mauermann, ML; Rajkumar, SV | 1 |
| Caballero, D; Caballero-Velázquez, T; Castilla-Llorente, C; Encinas, C; Heras, I; López-Corral, L; Martino, R; Pérez-Simón, JA; Rosiñol, L; Sampol, A; San Miguel, J; Serrano, D | 1 |
| Aleric, I; Bakovic, M; Bilic, E; Ceovic, R; Curtis, LM; Delimar, V; Desnica, L; Milos, O; Nemet, D; Pavletic, SZ; Pulanic, D; Pulanic, TK; Seiwerth, RS; Stipetic, MM; Vrhovac, R | 1 |
| Holyoake, TL; McQuaker, IG; Osborne, WL; Parker, AN | 1 |
| Estey, E; Gandhi, V; Kantarjian, H; Keating, MJ; Plunkett, W; Rios, MB | 1 |
| Hughes, RA; Lunn, MP; Schey, S; Wilson, HC | 1 |
1 review(s) available for fludarabine and Peripheral Nerve Diseases
| Article | Year |
|---|---|
Monoclonal Gammopathy-Associated Peripheral Neuropathy: Diagnosis and Management.
Topics: Administration, Intravenous; Biomarkers; Demyelinating Autoimmune Diseases, CNS; Diagnosis, Differential; Glycoproteins; Humans; Immunoglobulins; Immunologic Factors; Monoclonal Gammopathy of Undetermined Significance; Myeloablative Agonists; Peripheral Nervous System Diseases; Plasmapheresis; Prognosis; Rituximab; Vidarabine | 2017 |
2 trial(s) available for fludarabine and Peripheral Nerve Diseases
| Article | Year |
|---|---|
Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Cyclosporine; Drug Synergism; Female; Graft vs Host Disease; Hematologic Diseases; Humans; Immunosuppressive Agents; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Remission Induction; Reoperation; Salvage Therapy; T-Lymphocyte Subsets; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vidarabine | 2013 |
Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplantation; Colitis; Combined Modality Therapy; Conjunctivitis; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pancreatitis; Peripheral Nervous System Diseases; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine | 1993 |
3 other study(ies) available for fludarabine and Peripheral Nerve Diseases
| Article | Year |
|---|---|
High prevalence of small- and large-fiber neuropathy in a prospective cohort of patients with moderate to severe chronic GvHD.
Topics: Adolescent; Adult; Cohort Studies; Female; Graft vs Host Disease; Humans; Male; Middle Aged; Peripheral Nervous System Diseases; Prevalence; Prospective Studies; Small Fiber Neuropathy; Vidarabine; Young Adult | 2016 |
Fatal peripheral neuropathy following FLA chemotherapy.
Topics: Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Interactions; Fatal Outcome; Humans; Leukemia, Myeloid; Lung Diseases, Fungal; Male; Middle Aged; Peripheral Nervous System Diseases; Pyrimidines; Triazoles; Vidarabine; Voriconazole | 2004 |
Successful treatment of IgM paraproteinaemic neuropathy with fludarabine.
Topics: Aged; Aged, 80 and over; Female; Humans; Immunoglobulin M; Immunosuppressive Agents; Male; Middle Aged; Paraproteinemias; Peripheral Nervous System Diseases; Vidarabine | 1999 |